India's Proposed Tweak Of New Drug Rules: Bridge To Data Exclusivity?
A key Indian advisory panel is expected to consider a crucial tweak to certain regulations pertaining to the approval of “new drugs”, which domestic firms allege could facilitate a different form of data exclusivity and also limit competition.
You may also be interested in...
India's wide-ranging drug regulation overhaul plan, including a perpetual licensing system aimed at simplifying processes and potentially delinking licensing and enforcement responsibilities may well emerge as a double-edged sword.
Heavy-weight United Nations panel makes tough recommendations favoring compulsory licensing – an issue that has riled Big Pharma but has at least one industry proponent, Cipla's chair Yusuf Hamied, who talked to the Pink Sheet about the "excesses" of intellectual property rights.
Glenmark Pharmaceuticals has divested its API arm to the Nirma group for over $681m, a move that will deleverage the drug maker’s balance sheet as it seeks to evolve into an “innovative/brand led organization.”